Quick Takeaways
- IRON - Disc Medicine, Inc. has 30 insiders with reported activity on this page.
- Net insider value flow over the last year: -$110,641,891.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 30 Insiders of Disc Medicine, Inc.
- Symbol
- IRON on Nasdaq
- Location
- Watertown, MA
What Changed
- Buy value: ; sell value: $110,641,891.
- Net share flow: <span class="text-red-600">-1,394,810</span>.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$110,641,891.
Buys
$0
Shares: 0
Insiders: 0
Sells
$110,641,891
Shares: 1,394,810
Insiders: 8
Net
-$110,641,891
Shares: -1,394,810
Insiders: -8
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 48,022 | $0 | $3,068,479 | +$3,068,479 |
| 3-6 | 0 | 1,112,102 | $0 | $92,815,019 | +$92,815,019 |
| 6-9 | 0 | 215,713 | $0 | $13,778,124 | +$13,778,124 |
| 9-12 | 0 | 18,973 | $0 | $980,269 | +$980,269 |
Disc Medicine, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Braden M. Leonard | 10%+ Owner | $354,993,375 | Mixed | 26 Oct 2022 | ||
| AI DMI LLC | 10%+ Owner | $226,473,078 | -$59,873,462 | -21% | Filing P/S | 22 Oct 2025 |
| Atlas Venture Fund X, L.P. | 10%+ Owner | $108,274,637 | Filing P/S | 23 Jan 2024 | ||
| Novo Holdings A/S | 10%+ Owner | $73,790,726 | Mixed | 28 Jun 2023 | ||
| James B. Tananbaum | Director, 10%+ Owner | $27,837,975 | Mixed | 04 Oct 2021 | ||
| Atlas Venture Opportunity Fund II, L.P. | 10%+ Owner | $14,769,754 | Mixed | 29 Dec 2022 | ||
| John D. Quisel | Chief Executive Officer, Director | $14,210,383 | -$6,767,686 | -32% | Filing P/S | 17 Feb 2026 |
| Dr. Mona Ashiya | Director | $10,093,734 | Filing P/S | 11 Jun 2025 | ||
| ORBIMED ADVISORS LLC | Director | $10,093,734 | Filing P/S | 24 Mar 2025 | ||
| William Jacob Savage | Chief Medical Officer | $5,658,777 | -$2,474,409 | -30% | Filing P/S | 02 Mar 2026 |
| Pamela Stephenson | Chief Commercial Officer | $5,091,534 | -$347,679 | -6.4% | Filing P/S | 17 Feb 2026 |
| Jean M. Franchi | Chief Financial Officer | $4,902,349 | -$1,083,452 | -18% | Filing P/S | 25 Feb 2026 |
| Jonathan Yen-Wen Yu | Chief Operating Officer | $3,414,806 | -$2,744,023 | -45% | Filing P/S | 17 Feb 2026 |
| Rahul Khara | Chief Legal Officer | $3,279,594 | -$760,551 | -19% | Filing P/S | 17 Feb 2026 |
| Joanne Bryce | Chief Financial Officer | $1,600,937 | Mixed | 10 Jan 2024 | ||
| Kevin Bitterman | Director | $1,281,769 | -$36,590,630 | -97% | Filing P/S | 17 Dec 2025 |
| Brian Piekos | Cfo | $1,191,655 | Mixed | 31 May 2022 | ||
| Brian Richard MacDonald | Chief Innovation Officer | $904,615 | Mixed | 28 Jun 2023 | ||
| William Richard White | Director | $0 | Mixed | 11 Jun 2025 | ||
| Liam Ratcliffe | Director | Mixed | 11 Jun 2025 | |||
| Georges Gemayel | Director | Mixed | 16 Sep 2025 | |||
| Donald William Nicholson | Director | Mixed | 11 Jun 2025 | |||
| Nadim Ahmed | Director | Mixed | 14 Jul 2025 | |||
| Mark Chin | Director | Mixed | 11 Jun 2025 | |||
| Backstrom Jay T. | Director | Mixed | 29 Dec 2022 | |||
| Jason Patrick Meyenburg | Chief Executive Officer, Director | Mixed | 03 Jan 2022 | |||
| David Charles Lubner | Director | Mixed | 04 Oct 2021 | |||
| Tuyen Ong | Director | Mixed | 04 Oct 2021 | |||
| Carl L. Gordon | Director, 10%+ Owner | Mixed | 04 Oct 2021 | |||
| Jason P. Rhodes | Director, 10%+ Owner | Mixed | 04 Oct 2021 |
Top shareholders of Disc Medicine, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
|
Company |
14%
from 13D/G
|
5,450,222
|
$432,802,132 | — | 31 Dec 2025 | |
| Braden M. Leonard |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
5,247,500
|
$354,993,375 | — | 26 Oct 2022 | |
| AI DMI LLC |
3/4/5
13D/G
|
10%+ Owner |
8%
from 13D/G
|
2,814,379
|
$226,473,078 | -$59,873,462 | 22 Oct 2025 | |
| BlackRock, Inc. |
13F
|
Company |
6%
|
2,274,980
|
$180,656,161 | — | 31 Dec 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
13F
|
Company |
5.9%
|
2,228,924
|
$177,001,530 | $0 | 30 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.7%
|
1,767,680
|
$140,371,470 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
4.5%
|
1,698,005
|
$134,839,000 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
4.2%
|
1,581,127
|
$125,557,326 | — | 31 Dec 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
13D/G
|
Company |
4.1%
from 13D/G
|
1,518,274
|
$120,566,138 | — | 31 Dec 2025 | |
| Atlas Venture Life Science Advisors, LLC |
13F
|
Company |
4%
|
1,513,875
|
$120,216,814 | — | 31 Dec 2025 | |
| Atlas Venture Fund X, L.P. |
3/4/5
13D/G
|
10%+ Owner |
2.2%
from 13D/G
|
1,600,512
|
$108,274,637 | — | 23 Jan 2024 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
3.3%
|
1,260,000
|
$100,056,600 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
3.1%
|
1,187,991
|
$94,338,365 | — | 31 Dec 2025 | |
| ORBIMED ADVISORS LLC |
13F
13D/G
3/4/5
|
Company · Director |
4.5%
from 13D/G
|
1,067,550
|
$84,774,146 | — | 31 Dec 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
2.6%
|
988,401
|
$78,488,923 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
2.5%
|
957,833
|
$76,061,519 | — | 31 Dec 2025 | |
| Novo Holdings A/S |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,090,772
|
$73,790,726 | — | 28 Jun 2023 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
2%
|
754,195
|
$59,890,625 | — | 31 Dec 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
1.9%
|
735,000
|
$58,366,350 | — | 31 Dec 2025 | |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
— |
3%
|
1,026,489
|
$57,339,676 | $0 | 30 Jun 2025 | |
| Paradigm Biocapital Advisors LP |
13D/G
|
— |
3.5%
|
1,210,971
|
$57,097,283 | $0 | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.8%
|
684,958
|
$54,402,165 | — | 31 Dec 2025 | |
| BVF INC/IL |
13F
|
Company |
1.7%
|
650,000
|
$51,616,500 | — | 31 Dec 2025 | |
| Bain Capital Life Sciences Opportunities III, LP |
13D/G
|
— |
3.3%
|
983,500
|
$46,372,025 | $0 | 31 Dec 2024 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
1.4%
|
532,079
|
$42,252,392 | — | 31 Dec 2025 | |
| First Light Asset Management, LLC |
13F
|
Company |
1.4%
|
523,167
|
$41,544,691 | — | 31 Dec 2025 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
1.4%
|
511,163
|
$40,591,454 | — | 31 Dec 2025 | |
| Logos Global Management LP |
13F
|
Company |
1.3%
|
510,000
|
$40,499,100 | — | 31 Dec 2025 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
1.3%
|
499,391
|
$39,656,639 | — | 31 Dec 2025 | |
| Checkpoint Capital L.P. |
13F
|
Company |
1.2%
|
452,992
|
$35,972,095 | — | 31 Dec 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
1.2%
|
450,743
|
$35,793,502 | — | 31 Dec 2025 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
1%
|
395,392
|
$31,397,693 | — | 31 Dec 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1%
|
394,374
|
$31,317,239 | — | 31 Dec 2025 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
0.95%
|
357,836
|
$28,415,757 | — | 31 Dec 2025 | |
| James B. Tananbaum |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
428,745
mixed-class rows
|
$27,837,975 | — | 04 Oct 2021 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.89%
|
337,050
|
$26,765,141 | — | 31 Dec 2025 | |
| Palo Alto Investors LP |
13F
|
Company |
0.84%
|
317,456
|
$25,209,181 | — | 31 Dec 2025 | |
| Foresite Capital Management V, LLC |
13F
|
Company |
0.79%
|
299,069
|
$23,749,069 | — | 31 Dec 2025 | |
| Saturn V Capital Management LP |
13F
|
Company |
0.79%
|
298,429
|
$23,698,247 | — | 31 Dec 2025 | |
| LOOMIS SAYLES & CO L P |
13F
|
Company |
0.75%
|
282,409
|
$22,426,098 | — | 31 Dec 2025 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
0.66%
|
250,000
|
$19,852,500 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.65%
|
247,039
|
$19,617,367 | — | 31 Dec 2025 | |
| Aberdeen Group plc |
13F
|
Company |
0.62%
|
234,358
|
$18,610,369 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.6%
|
228,070
|
$18,111,039 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.59%
|
223,575
|
$17,747,193 | — | 31 Dec 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.59%
|
221,761
|
$17,610,041 | — | 31 Dec 2025 | |
| Opaleye Management Inc. |
13F
|
Company |
0.53%
|
200,000
|
$15,882,000 | — | 31 Dec 2025 | |
| TimesSquare Capital Management, LLC |
13F
|
Company |
0.5%
|
187,777
|
$14,911,372 | — | 31 Dec 2025 | |
| Atlas Venture Opportunity Fund II, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
218,326
|
$14,769,754 | — | 29 Dec 2022 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.49%
|
184,779
|
$14,673,300 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for Disc Medicine, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| William Jacob Savage | IRON | Common Stock | Sale | -7.97% | $486,069 | $65.88 | -7,378 | 85,211 | 02 Mar 2026 | Direct |
| Jean M. Franchi | IRON | Common Stock | Sale | -0.49% | $24,377 | $69.06 | -353 | 70,990 | 25 Feb 2026 | Direct |
| Jean M. Franchi | IRON | Common Stock | Sale | -9.03% | $463,573 | $65.47 | -7,081 | 71,343 | 18 Feb 2026 | Direct |
| Jean M. Franchi | IRON | Common Stock | Sale | -4.94% | $256,154 | $62.86 | -4,075 | 78,424 | 17 Feb 2026 | Direct |
| Rahul Khara | IRON | Common Stock | Sale | -5.18% | $179,340 | $62.86 | -2,853 | 52,173 | 17 Feb 2026 | Direct |
| Pamela Stephenson | IRON | Common Stock | Sale | -6.39% | $347,679 | $62.86 | -5,531 | 80,998 | 17 Feb 2026 | Direct |
| William Jacob Savage | IRON | Common Stock | Sale | -3.4% | $204,672 | $62.86 | -3,256 | 92,589 | 17 Feb 2026 | Direct |
| Jonathan Yen-Wen Yu | IRON | Common Stock | Sale | -5.61% | $203,101 | $62.86 | -3,231 | 54,324 | 17 Feb 2026 | Direct |
| John D. Quisel | IRON | Common Stock | Sale | -5.54% | $833,775 | $62.86 | -13,264 | 226,064 | 17 Feb 2026 | Direct |
| Rahul Khara | IRON | Common Stock | Award | 44.7% | 17,000 | 55,026 | 10 Feb 2026 | Direct | ||
| Rahul Khara | IRON | Stock Option (Right to Buy) | Award | 25,500 | 25,500 | 10 Feb 2026 | Direct | |||
| Pamela Stephenson | IRON | Common Stock | Award | 24.4% | 17,000 | 86,529 | 10 Feb 2026 | Direct | ||
| Pamela Stephenson | IRON | Stock Option (Right to Buy) | Award | 25,500 | 25,500 | 10 Feb 2026 | Direct | |||
| William Jacob Savage | IRON | Common Stock | Award | 21.6% | 17,000 | 95,845 | 10 Feb 2026 | Direct | ||
| William Jacob Savage | IRON | Stock Option (Right to Buy) | Award | 25,500 | 25,500 | 10 Feb 2026 | Direct | |||
| Jonathan Yen-Wen Yu | IRON | Common Stock | Award | 41.9% | 17,000 | 57,555 | 10 Feb 2026 | Direct | ||
| Jonathan Yen-Wen Yu | IRON | Stock Option (Right to Buy) | Award | 25,500 | 25,500 | 10 Feb 2026 | Direct | |||
| Jean M. Franchi | IRON | Common Stock | Award | 29.9% | 19,000 | 82,499 | 10 Feb 2026 | Direct | ||
| Jean M. Franchi | IRON | Stock Option (Right to Buy) | Award | 25,500 | 25,500 | 10 Feb 2026 | Direct | |||
| John D. Quisel | IRON | Common Stock | Award | 30% | 55,200 | 239,328 | 10 Feb 2026 | Direct | ||
| John D. Quisel | IRON | Stock Option (Right to Buy) | Award | 82,800 | 82,800 | 10 Feb 2026 | Direct | |||
| Rahul Khara | IRON | Common Stock | Sale | -2.58% | $69,740 | $69.74 | -1,000 | 37,793 | 20 Jan 2026 | Direct |
| Rahul Khara | IRON | Common Stock | Options Exercise | 2.65% | 1,000 | 38,793 | 20 Jan 2026 | Direct | ||
| Rahul Khara | IRON | Stock Option (Right to Buy) | Options Exercise | -4.49% | -1,000 | 21,270 | 20 Jan 2026 | Direct | ||
| Rahul Khara | IRON | Common Stock | Sale | -14.7% | $511,472 | $78.69 | -6,500 | 37,793 | 02 Jan 2026 | Direct |
| Rahul Khara | IRON | Common Stock | Options Exercise | 17.2% | 6,500 | 44,293 | 02 Jan 2026 | Direct | ||
| Rahul Khara | IRON | Stock Option (Right to Buy) | Options Exercise | -22.6% | -6,500 | 22,270 | 02 Jan 2026 | Direct | ||
| William Jacob Savage | IRON | Common Stock | Options Exercise | 4.15% | 3,143 | 78,845 | 22 Dec 2025 | Direct | ||
| William Jacob Savage | IRON | Stock Option (Right to Buy) | Options Exercise | -54.5% | -3,143 | 2,628 | 22 Dec 2025 | Direct | ||
| John D. Quisel | IRON | Common Stock | Options Exercise | 7.16% | 12,300 | 184,128 | 19 Dec 2025 | Direct | ||
| John D. Quisel | IRON | Stock Option (Right to Buy) | Options Exercise | -6.2% | -12,300 | 186,120 | 19 Dec 2025 | Direct | ||
| Kevin Bitterman | IRON | Common Stock | Sale | -5.11% | $68,968 | $91.47 | -754 | 14,013 | 17 Dec 2025 | See footnote |
| Kevin Bitterman | IRON | Common Stock | Sale | -83% | $6,288,535 | $91.24 | -68,923 | 14,161 | 16 Dec 2025 | See footnote |
| Kevin Bitterman | IRON | Common Stock | Sale | -100% | $643,090 | $91.87 | -7,000 | 0 | 15 Dec 2025 | Direct |
| Kevin Bitterman | IRON | Common Stock | Options Exercise | 7,000 | 7,000 | 15 Dec 2025 | Direct | |||
| Kevin Bitterman | IRON | Common Stock | Sale | -68.7% | $5,722,608 | $91.28 | -62,693 | 28,520 | 15 Dec 2025 | See footnote |
| Kevin Bitterman | IRON | Stock Option (Right to Buy) | Options Exercise | -100% | -7,000 | 0 | 15 Dec 2025 | Direct | ||
| William Jacob Savage | IRON | Common Stock | Sale | -14.8% | $1,194,372 | $91.22 | -13,093 | 75,702 | 15 Dec 2025 | Direct |
| Kevin Bitterman | IRON | Common Stock | Sale | -52.3% | $4,204,407 | $92.39 | -45,507 | 41,519 | 12 Dec 2025 | See footnote |
| John D. Quisel | IRON | Common Stock | Sale | -18.9% | $3,721,931 | $93.05 | -40,000 | 171,828 | 11 Dec 2025 | Direct |
| John D. Quisel | IRON | Common Stock | Options Exercise | 23.3% | 40,000 | 211,828 | 11 Dec 2025 | Direct | ||
| John D. Quisel | IRON | Stock Option (Right to Buy) | Options Exercise | -34.7% | -40,000 | 75,375 | 11 Dec 2025 | Direct | ||
| Jonathan Yen-Wen Yu | IRON | Common Stock | Sale | -42.5% | $2,540,923 | $84.70 | -30,000 | 40,555 | 11 Nov 2025 | Direct |
| Jonathan Yen-Wen Yu | IRON | Common Stock | Options Exercise | 74% | 30,000 | 70,555 | 11 Nov 2025 | Direct | ||
| Jonathan Yen-Wen Yu | IRON | Stock Option (Right to Buy) | Options Exercise | -79.1% | -30,000 | 7,941 | 11 Nov 2025 | Direct | ||
| Ai Dmi Llc | IRON | Common Stock | Sale | -20.9% | $59,873,462 | $80.47 | -744,047 | 2,814,379 | 22 Oct 2025 | Direct |
| Kevin Bitterman | IRON | Common Stock | Sale | -15.4% | $6,223,934 | $88.91 | -70,000 | 385,549 | 17 Oct 2025 | See footnote |
| Kevin Bitterman | IRON | Common Stock | Sale | -0.3% | $109,882 | $77.11 | -1,425 | 477,036 | 16 Oct 2025 | See footnote |
| Kevin Bitterman | IRON | Common Stock | Sale | -4.43% | $1,711,436 | $77.23 | -22,160 | 478,461 | 15 Oct 2025 | See footnote |
| Kevin Bitterman | IRON | Common Stock | Sale | -12.6% | $5,079,007 | $70.58 | -71,961 | 500,621 | 08 Oct 2025 | See footnote |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.